Early surgery improves outcome and survival in patients with hydrocephalus

Early surgery improved both outcome and survival in patients with the neurological condition hydrocephalus, while mortality was higher in those who had to wait, according to a thesis from the University of Gothenburg, Sweden. These results add to pressure on efforts to keep waiting lists for surgery short.

Hydrocephalus (idiopathic Normal Pressure Hydrocephalus, iNPH) is a treatable neurological condition that causes gait problems, cognitive impairment or dementia, and incontinence. It is characterized by enlarged, fluid-filled brain cavities, and is commonly referred to as "water on the brain."

Older people are especially prone to fall ill with iNPH, and of those aged 70 and over as many as 2% are estimated to be affected. Studies show that only a minority gets diagnosed and treated.

One reason may be that the condition is insufficiently known; another is that the symptoms can be mistaken for normal aging or attributed to other health problems.

The treatment is a neurosurgical operation in which a thin plastic tube, known as a shunt, is inserted into the brain to drain excess cerebrospinal fluid. It is a highly effective treatment:

Patients generally feel considerably better after the operation and can live a more independent life. Eight out of ten patients who undergo surgery benefit from this treatment.

Mortality linked to waiting time

As described in her thesis at Sahlgrenska Academy, Kerstin Andrén, a neurologist at Sahlgrenska University Hospital, studied several factors with a bearing on treatment outcome and patients' life expectancy after shunt surgery for iNPH.

Two studies in her thesis concerned a group of 33 patients who, owing to inadequate neurosurgical capacity, were obliged to wait 6-24 months (more than a year on average) for their shunt operations at Sahlgrenska University Hospital.

In many cases, these patients' health deteriorated considerably in the waiting period, and some needed wheelchairs.

Following surgery, they showed less improvement in gait, balance, and mental functions than another group of 69 patients whose surgery took place within three months.

Moreover, at a five-year follow-up, 17 of the 33 patients (52%) were found to have died. Their mortality was more than double the death rate in the group who did not have to wait, in which 16 out of 69 (23%) had died.

This is the first time we've been able to study what happens to patients with hydrocephalus when their treatment is delayed. This is vital information for prioritizing these patients."

Kerstin Andrén, Neurologist, Sahlgrenska University Hospital

Long-term benefits of surgery

In the longer term, six out of ten patients remain in better health after their shunt surgery than before. This is evident from the section of the thesis reporting on Andrén's study of two- to six-year postoperative outcomes in 979 patients from all over Sweden.

Even the quarter who suffered from complications and needed to undergo further surgery perceived the treatment effects as beneficial in the long term.

As a group, the patients' mortality rate was twice as high as that of the general population and higher for those with more severe symptoms.

However, patients with the best treatment outcomes from the operation were found not to be at a higher risk of dying than the general population.

The clinical data in the thesis were collected from Sahlgrenska University Hospital, the Swedish Hydrocephalus Quality Registry, and the Swedish Cause of Death Register. The control group from the general population was selected by Statistics Sweden (SCB).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New funding for innovative dementia vaccine research